Search Results

May 08, 2026, 03:00 ET Angel Yeast at Vitafoods Europe 2026, Pioneering Global Nutrition and Health Trends with AngeoPro™ Yeast Protein

Fermented Ginseng.Strategic OutlookThis participation in Vitafoods Europe served as a critical platform for Angel Yeast to align its R&D roadmap with the specific demands of the European market. By engaging with international industry leaders, the company has solidified its commitment

More news about: Angel Yeast

May 08, 2026, 02:30 ET Update on FDA Priority Review of LEQEMBI® IQLIK™ (lecanemab-irmb) Subcutaneous Injection as a Starting Dose for Early Alzheimer's Disease

Concept), we aim to effectively achieve social good in the form of relieving anxiety over health and reducing health disparities. With a global network of R&D facilities, manufacturing sites and marketing subsidiaries, we strive to create and deliver innovative products to target diseases with high unmet

More news about: Eisai Co., Ltd.

May 08, 2026, 01:17 ET Persistent obtient la spécialisation Databricks Brickbuilder pour les secteurs de la santé et des sciences de la vie, lui permettant d'élargir l'offre de solutions de données et d'IA prêtes à la production pour les environnements réglementés

à l'échelle de l'entreprise, en garantissant la précision, la gouvernance et l'interopérabilité dans l'ensemble des flux de travail cliniques, de R&D, commerciaux et opérationnels. Les technologies de base de Databricks sont sous-jacentes. Delta Lake fournit une base de données fiable en ce qui concerne

More news about: Persistent Systems

May 07, 2026, 23:55 ET Hikvision publikuje Raport ESG 2025, realizując ideę zrównoważonego rozwoju poprzez „Technologię dla dobra"

działalnością i 1 553 nowo przyznanych patentach w 2025 r.Zapewnienie zgodności i ochrony danychPoprzez wdrożenie najlepszych globalnych praktyk, Hikvision skutecznie włącza wymogi zgodności do swoich codziennych działań. W 2025 r. firma otrzymała certyfikat ISO 37301. Podążając za najnowszymi

More news about: Hikvision

May 07, 2026, 23:42 ET Hikvision publikuje wyniki finansowe za rok 2025 i pierwszy kwartał 2026 r.

HANGZHOU, Chiny, 8 maja 2026 r. /PRNewswire/ -- Spółka Hikvision opublikowała wyniki finansowe za cały rok 2025 oraz pierwszy kwartał 2026 r., wykazując stabilny wzrost i poprawę w zakresie działalności operacyjnej.

More news about: Hikvision

May 07, 2026, 23:37 ET Hikvision publie ses résultats financiers pour l'année 2025 et le premier trimestre 2026

l'environnement.Engagement soutenu en faveur de la R&D et de l'innovationL'innovation technologique reste le moteur du développement de Hikvision. En 2025, l'entreprise a investi 11,75 milliards RMB (1,65 milliard de dollars) dans la R&D, ce qui représente 12,70 % de son chiffre d'affaires

More news about: Hikvision

May 07, 2026, 20:30 ET Chance Pharma Announces NMPA Acceptance of New Drug Application for Investigational Respiratory Drug CXG87

particularly those with airflow limitations, such as low inspiratory flow rate or reduced lung capacity."Dr. Lan Chen, Co-founder and Head of R&D at Chance Pharma, commented: "We were privileged to be able to further refine and enhance a well-established inhaled product, Symbicort®

More news about: Chance Pharmaceuticals

May 07, 2026, 19:19 ET /C O R R E C T I O N -- App Defense Alliance/

More news about: App Defense Alliance

May 07, 2026, 18:54 ET /C O R R E C T I O N -- Braille Institute of America/

/C O R R E C T I O N – Braille Institute of America/ In the news release, 2026 Braille Challenge Finalists Announced Following Record-Breaking Global Participation, issued 07-May-2026 by Braille Institute of America over PR Newswire, we are advised by the company that changes have been made. The

More news about: Braille Institute of America

May 07, 2026, 18:00 ET Sunseeker Robotics Unveils X Gen 2 Series Robot Mower at Spring Spectacular, Advancing Wire-Free Lawn Care for North America

intelligent, hassle-free lawn care means for both commercial properties and modern households. This new series is the culmination of our years of R&D in smart outdoor robotics, merging industry-leading precision engineering, cutting-edge AI technology and intuitive everyday usability, to deliver

More news about: Sunseeker Robotics

May 07, 2026, 16:30 ET CON EDISON REPORTS 2026 FIRST QUARTER EARNINGS

gas service in Manhattan, the Bronx, parts of Queens and parts of Westchester, and steam service in Manhattan; Orange and Rockland Utilities, Inc. (O&R), a regulated utility serving customers in a 1,300-square-mile area in southeastern New York State and northern New Jersey; and Con Edison Transmission,

More news about: Consolidated Edison, Inc.

May 07, 2026, 16:15 ET Nektar Therapeutics Reports First Quarter 2026 Financial Results

due to a decrease in G&A expenses, partially offset by an increase in R&D expenses. R&D expense in the first quarter of 2026 was $35.7 million as compared to $30.5 million for the first quarter of 2025. R&D expense increased primarily due to increased expenses for the development

More news about: Nektar Therapeutics

May 07, 2026, 16:15 ET Hyperliquid Strategies Inc Reports Financial Results for the Quarter Ended March 31, 2026

$3.1 million in staking revenue from HYPE holdings.$1.9 million in interest income.$10.7 million in SG&A and R&D expenses.$165.4 million in net loss.Net loss primarily attributable to $64.0 million in net unrealized losses on HYPE tokens, a one-time

More news about: Hyperliquid Strategies Inc

May 07, 2026, 16:15 ET Post Holdings Reports Results for the Second Quarter of Fiscal Year 2026; Affirms Fiscal Year 2026 Outlook

r.Impairment of goodwill: Post has excluded expenses

More news about: Post Holdings, Inc.

May 07, 2026, 16:05 ET Enliven Therapeutics Reports First Quarter Financial Results and Provides a Business Update

securities totaling $452.4 million, which is expected to provide cash runway into the first half of 2029.Research and development (R&D) expenses: R&D expenses were $20.7 million for the first quarter of 2026, compared to $24.9 million for the first quarter of 2025.General

More news about: Enliven Therapeutics, Inc.

May 07, 2026, 16:05 ET Ginkgo Bioworks Reports First Quarter 2026 Financial Results, Completes Divestiture of Biosecurity and Continues to Scale Autonomous Lab

Ginkgo at the frontier of scientific innovation in the scientific (Nature), trade (R&D World), mainstream (Forbes, The Washington Post), and tech press (Sequoia's Training Data, TBPN)Policymakers and heads of R&D visit for our internal demonstrations. During SLAS 2026, over 500 visitors came

More news about: Ginkgo Bioworks

May 07, 2026, 16:00 ET Novavax to Participate in BofA Securities 2026 Health Care Conference

technology, capital-efficient research and development (R&D) innovation and a lean and efficient operating model. This includes maximizing impact through partnerships for its marketed products (Nuvaxovid™, R21/Matrix-M™), Matrix technology and R&D assets. Please visit

More news about: Novavax, Inc.